|
Drug Topics
Hospital
Pharmacists' Report
DrugTopics.com
November 17, 2011 |
CLINICAL NEWS
As many as 95% of stroke patients with atrial fibrillation received prescriptions for anticoagulants in 2010 if they were treated at hospitals that participate in the "Get With The Guidelines – Stroke" program, researchers found, which is up from 88% in 2003. » More |
|
Emergency department patients over age 75 who complain of pain are about 20% less likely to have their pain treated than middle-aged patients, according to a new study.
» More |
ADVERTISEMENT
Resource Center: Oral Anticoagulation in Atrial Fibrillation
Atrial fibrillation afflicts more than 2.3 million persons in the United States and is expected to increase 2.5-fold by 2050. To find risk stratifying tools and articles on emerging oral anticoagulant therapies,
 click here. |
CONTINUING EDUCATION
In carrying out Risk Evaluation and Mitigation Strategies associated with long-acting opioids, the pharmacist plays a multidimensional role in this effort, which includes educating patients, prescribers, and the community at large, being vigilant to signs of overprescribing or abuse, and recognizing the biopsychosocial factors that put pain patients at risk for substance abuse. » Click here to login and take the exams. |
CLINICAL NEWS
In a phase III trial, the second-generation selective estrogen receptor modulator (or SERM) toremifene significantly decreased new vertebral fractures during androgen deprivation therapy in men under age 80. » More |
FDA ACTIONS
FDA has approved rivaroxaban (Xarelto, Janssen Pharmaceuticals) to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. » More |
|
FDA has approved cetuximab (Erbitux, Bristol-Myers Squibb) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer. » More |
|
FDA has approved Hemacord (New York Blood Center), the first licensed hematopoietic progenitor cells-cord cell therapy. » More |
|
FDA has issued a complete response letter to the New Drug Application for the extended-release intravitreal insert (Iluvien, Alimira Sciences) for the treatment of diabetic macular edema associated with diabetic retinopathy. » More |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
